Apixaban with antiplatelet therapy after acute coronary syndrome

John H Alexander, Renato D Lopes, Stefan James, Rakhi Kilaru, Yaohua He, Puneet Mohan, Deepak L Bhatt, Shaun Goodman, Freek W Verheugt, Marcus Flather, Kurt Huber, Danny Liaw, Steen E Husted, Jose Lopez-Sendon, Raffaele De Caterina, Petr Jansky, Harald Darius, Dragos Vinereanu, Jan H Cornel, Frank CoolsDan Atar, Jose Luis Leiva-Pons, Matyas Keltai, Hisao Ogawa, Prem Pais, Alexander Parkhomenko, Witold Ruzyllo, Rafael Diaz, Harvey White, Mikhail Ruda, Margarida Geraldes, Jack Lawrence, Robert A Harrington, Lars Wallentin, APPRAISE-2 Investigators

Research output: Contribution to journalArticlepeer-review

934 Citations (Scopus)


Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.
Original languageEnglish
Pages (from-to)699-708
Number of pages10
JournalNew England Journal of Medicine
Issue number8
Publication statusPublished - 25 Aug 2011


  • Acute Coronary Syndrome
  • Aged
  • Angina, Unstable
  • Aspirin
  • Double-Blind Method
  • Drug Therapy, Combination
  • Factor Xa
  • Female
  • Hemorrhage
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Proportional Hazards Models
  • Pyrazoles
  • Pyridones
  • Stroke
  • Treatment Outcome

Cite this